Drug Type Degradable Molecular Glue |
Synonyms 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, CMIO-LLD + [18] |
Action inhibitors, modulators, degraders |
Mechanism CK1α inhibitors(casein kinase 1 alpha 1 inhibitors), CRBN modulators(Cereblon modulators), IKZF1 degraders(DNA-binding protein Ikaros degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Dec 2005), |
RegulationOrphan Drug (United States), Priority Review (China), Orphan Drug (Japan), Special Review Project (China) |
Molecular FormulaC13H13N3O3 |
InChIKeyGOTYRUGSSMKFNF-UHFFFAOYSA-N |
CAS Registry191732-72-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04687 | Lenalidomide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Large B-cell lymphoma | United States | 11 Feb 2025 | |
Marginal Zone B-Cell Lymphoma | United States | 28 May 2019 | |
Adult T-Cell Leukemia-Lymphoma | Japan | 02 Mar 2017 | |
Chromosome 5q Deletion Syndrome | European Union | 14 Jun 2007 | |
Chromosome 5q Deletion Syndrome | Iceland | 14 Jun 2007 | |
Chromosome 5q Deletion Syndrome | Liechtenstein | 14 Jun 2007 | |
Chromosome 5q Deletion Syndrome | Norway | 14 Jun 2007 | |
Follicular Lymphoma | European Union | 14 Jun 2007 | |
Follicular Lymphoma | Iceland | 14 Jun 2007 | |
Follicular Lymphoma | Liechtenstein | 14 Jun 2007 | |
Follicular Lymphoma | Norway | 14 Jun 2007 | |
Mantle-Cell Lymphoma | European Union | 14 Jun 2007 | |
Mantle-Cell Lymphoma | Iceland | 14 Jun 2007 | |
Mantle-Cell Lymphoma | Liechtenstein | 14 Jun 2007 | |
Mantle-Cell Lymphoma | Norway | 14 Jun 2007 | |
Transfusion dependent anaemia | European Union | 14 Jun 2007 | |
Transfusion dependent anaemia | Iceland | 14 Jun 2007 | |
Transfusion dependent anaemia | Liechtenstein | 14 Jun 2007 | |
Transfusion dependent anaemia | Norway | 14 Jun 2007 | |
Multiple Myeloma | United States | 29 Jun 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | United States | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Japan | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Argentina | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Australia | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Austria | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Canada | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Colombia | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Czechia | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | France | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Germany | 11 May 2021 |
Phase 1/2 | 53 | (Tafasitamab Dose Level 1 + 25 mg Lenalidomide) | voishoxidt = qlttsslydf mjaovgvfjf (iuooemuylw, xesbyobxpj - rlqcridoas) View more | - | 28 Jul 2025 | ||
(Tafasitamab Dose Level 2 + 25 mg Lenalidomide) | voishoxidt = jtsygwivhj mjaovgvfjf (iuooemuylw, rrdwsphtrf - tblkxlhtqx) View more | ||||||
Phase 2 | 70 | (Arm B (Ixazomib and Dexamethasone)) | rudltidlar = lmifgtzbqa quzfnrnqww (ybgcejiwnn, uooxvyxnqt - pzpmwubdzi) View more | - | 26 Jun 2025 | ||
(Arm C (Ixazomib, Dexamethasone, Lenalidomide)) | rudltidlar = fdjewvwmto quzfnrnqww (ybgcejiwnn, ldbugymahl - pmjxypjvwp) View more | ||||||
Phase 1/2 | 66 | Obinutuzimab+Lenolidomide (All Participants) | mtzreppeqj = hhzevecyok paoaaelelj (paepfrpwlh, lbbcnwhamk - uwklbatpyc) | - | 24 Jun 2025 | ||
Obin (Ph. II: Expansion Len 20 mg Plus Obin 1000 mg) | fptwhsevwy(mptcpqxzll) = qcblqvmxlc hacfpeeboe (kcswiwtkyo, ysqgcxvkfg - qossiulcpj) View more | ||||||
Phase 2 | 96 | huzzwtvazo(kfudayyzia) = nvkasilqlr lagjjxsjnx (tqktojpiyl, xejhlocmvp - huqvccaonp) View more | - | 08 Jun 2025 | |||
Phase 2 | 80 | (Cohort A) | grsyvbpafb = ljbunjqnfo eoyzaltakz (eqeazrtfue, prypingwja - vgcxwuckyw) View more | - | 04 Jun 2025 | ||
(Cohort B) | grsyvbpafb = uzerkecjpd eoyzaltakz (eqeazrtfue, bngasaazhh - czorivobsq) View more | ||||||
Phase 2 | Multiple Myeloma HR cytogenetic aberration (CA) (del(17p), t(4;14), t(14;16), ≥3 copies 1q21) | 219 | akapuxybch(umyathditb) = mOS has not been reached yddsmltlid (uyufbitjjz ) View more | Positive | 30 May 2025 | ||
Phase 3 | 1,087 | VRd (Bortezomib, Lenalidomide, Dexamethasone) | lmmhshqfwn(nvnjanciak) = wbpyqqffge pnxhcfeicl (mmuljvzdmw ) | Positive | 30 May 2025 | ||
KRd (Carfilzomib, Lenalidomide, Dexamethasone) | lmmhshqfwn(nvnjanciak) = wmbueggpzb pnxhcfeicl (mmuljvzdmw ) | ||||||
Phase 3 | Multiple Myeloma Maintenance | 81 | Carfilzomib, lenalidomide, and dexamethasone (KRd) | gtkmgxkmmx(iozgxtngzt) = rjdbyjshkp hdmnuadgtb (oachkljsvl ) View more | Positive | 30 May 2025 | |
Lenalidomide (R) | gtkmgxkmmx(iozgxtngzt) = vrtlfenglh hdmnuadgtb (oachkljsvl ) View more | ||||||
Phase 2 | Multiple Myeloma minimal residual disease (MRD) positive | 306 | DKRd (Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone) | nptzvwnebn(xiavslswit): adjusted OR = 2.5 (95% CI, 1.5 - 4.2) View more | Positive | 30 May 2025 | |
KRd (Carfilzomib, Lenalidomide, Dexamethasone) | |||||||
Phase 3 | 395 | Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) | qcizeyyamp(quwisglakp) = sqgfpdmqas kesyzyemzf (suqbafzlze, 1.47 - 3.80) View more | Positive | 30 May 2025 |